Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Integrated Diagnostics Holdings's Revenue for the
three
months ended in Mar. 2026 was $43.63 Mil. Integrated Diagnostics Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $20.97 Mil.
Hence, Integrated Diagnostics Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Integrated Diagnostics Holdings Receivables Turnover Related Terms
Integrated Diagnostics Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IDHC vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a Receivables Turnover of 2.08 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integrated Diagnostics Holdings and its competitors. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #161 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 79.7%.
Is Integrated Diagnostics Holdings' Receivables Turnover too high?
Integrated Diagnostics Holdings' current Receivables Turnover is 2.08. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Integrated Diagnostics Holdings' value of 2.08 is 61.3% below this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #161 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #161 out of 202 companies for Receivables Turnover. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median Receivables Turnover is 5.38. Integrated Diagnostics Holdings' value of 2.08 is 61.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current Receivables Turnover of 2.08 is 61.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current Receivables Turnover is 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.51 — trading 13.6% below its estimated fair value. The current Receivables Turnover is 2.08 and 61.3% below the Medical Diagnostics & Research industry median of 5.38. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Receivables Turnover is 2.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.51 is trading 13.6% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
Receivables Turnover: 2.08
GF Value™: $0.59 vs. price of $0.51 (13.6% below fair value)
Industry Position: 61.3% below the Medical Diagnostics & Research median (#161 of 202)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
